Crf analogs

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 14/575 (2006.01) A61K 38/22 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2086827

2086827 9221372 PCTABS00017 Analogs of CRF, which are based upon hCRF, oCRF and alpha-helical CRF, are disclosed that can be administered to achieve a substantial elevation of ACTH, .beta.-endorphin, .beta.-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone levels. Analogs include those having the formula (see SEQ ID NO:9): Y-Ser-Xaa2-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Le_ u-Xaa20-Xaa21-Xaa22-Xaa23-Xaa24-Xaa25-Gl n-Leu-Ala-Gln-Gln-Ala-Xaa32-Ser-Asn-Arg-Lys-Leu-Xaa38-Xaa39-Ile-Xaa41-NH2, wherein Y is an acyl group having 7 or fewer carbon atoms or hydrogen; Xaa2 is Glu or Gln; Xaa20 is Ala or Glu; Xaa21 is Met or Nle; Xaa22 is Ala or Thr; Xaa23 is Arg or Lys; Xaa24 is D-Ala or Ala; Xaa25 is Glu or Asp; Xaa32 is D-His or His; Xaa38 is Met, Nle or Leu; Xaa39 is Ala, Glu or Asp; Xaa41 is Ile or Ala; provided however that at least one of Xaa20 and Xaa39 is Ala and that the N-terminus may be shortened by a sequence of up to about 5 residues. One example is [Ala20]-oCRF. These analogs or their pharmaceutically acceptable salts, dispersed in an acceptable liquid or solid carrier, can be administered to humans.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Crf analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crf analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crf analogs will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1622219

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.